High levels of soluble IFN γ receptor α chain in the plasma of rheumatoid arthritis patients

Farrar MA, Schreiber RD. The molecular cell biology of interferon gamma and its receptor. Ann. Rev. Immunol. 1993; 11: 571–611. Trinchieri G, Perussia B. Immune interferon: A pleiotropic lymphokine with multiple effects. Immunol. Today 1985; 6: 131. Revel M, Chebath J. Interferon-activated genes. TIBS 1986; 11: 166–170. Aguet M, Dembic Z, Merlin G. Molecular cloning and expression of the human interferon gamma receptor. Cell 1988; 55: 273–80. Soh J, Donnelly RJ, Kotenko S, Mariano MT, Cook JR, Wang N, Emanuel S, Schwartz B, Miki T, Pestka S. Identification and sequence of an accessory factor required for activation of the human interferon gamma receptor. Cell 1994; 76: 793–802. Aguet M, Merlin G. Purification of human gamma interferon receptors by sequential affinity chromatography on immobilized monoclonal anti-receptor antibodies and human gamma interferon. J. Exp. Med. 1988; 165: 988–99. Rubin LA, Jay G, Nelson DL. The released interleukin 2 receptor binds interleukin 2 efficiently J. Immunol. 1986; 137: 3841–4. Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J. Exp. Med. 1989; 170: 1–6. Engelmann HD, Aderka M, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 1989; 264: 11974–80. Mosley B, Beckmann MP, March CJ, Idzerda RL, Gimpel SD, Van den Bos T, Friend D, Alper A, Anderson D, Jackson J, Wignall JM, Smith C, Gallis B, Sims JE, Urdal D, Widmer MB, Cosman D, Park LS. The murine interleukin-4 receptor: molecular cloning and characterisation of secreted and membrane bound forms. Cell 1989; 59: 335–48. Goodwin RG, Friend D, Ziegler SF, Jerzy R, Falk BA, Gimpel S, Cosman D, Dower SK, March CJ, Namen AE, Park LS. Cloning of the human and murine interleukin-7 receptors: demonstration of soluble form and homology to a new receptor superfamily. Cell 1990; 60: 941–51. Novick D, Shulman L, Chen L, Revel M. Enhancement of interleukin-6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody. Cytokine 1992; 4: 6–11. Bello I, Lopez-Saura P, Aguet M. Receptores solubles para interferon. Biotecnologia Aplicada 1990; 7: 290–300. Harris Jr. ED, Rheumatoid arthritis: Pathophysiology and implications for therapy. N. Engl. J.Med. 1990; 322: 1277–89. Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanism of joint destruction in rheumatoid arthritis: two cellular mechanism explain joint destruction. Annals Rheum Dis. 1993; 52: S39–47. ai]16._ Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J. Immunol. 1983; 130; 2651–5. Miossec P, Elhamiani M, Edmonds-Alt, Sany J, Hirn M. Functional studies of soluble low affinity interleukin-2 receptors in rheumatoid synovial fluid. Arthritis Rheumatism 1990; 33: 1688–94. Miossec P, Elhamiani M, Edmonds-Alt, Sany J, Hirn M. Functional studies of soluble low affinity interleukin-2 receptors in rheumatoid synovial fluid. Arthritis Rheumatism 1990; 33: 1688–94. Hopkins SJ, Meager A. Cytokines in synovial fluid: II. The presence of tumor necrosis factor and interferon. Clin. Exp. Immunol. 1988;73: 88–92. Fish EN, Soto E, Keystone E. Characterisation of interferon gamma defect in rheumatoid arthritis. J. Interf. Res. 1991, 11: S102. Garotta G, Ozmen L, Fountoulakis M, Dembic Z, van Loon PGMA, Stuber D. Human interferon gamma receptor. J. Biol. Chem. 1990; 265: 6908–15. Ropes MW, Bennet GA, Cobb S, Jacox R, Jessar RA. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull. Rheum. Dis. 1958; 9: 175–6. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680. Fountoulakis M, Juranville JF, Stuber D, Weibel EK, Garotta, G. Purification and biochemical characterization of a soluble human interferon gamma receptor expressed in Escherichia coli. J. Biol. Chem. 1990, 265; 13268–75. Novelli F, Giovarelli M, Gentz R, Zucca M, di Pierro F, Garotta G, Forni G. Modulation of interferon gamma receptor during human T lymphocyte alloactivation. Europ. J Immunol. 1993, 23: 1226–31. Trincheri G, Santoli D. Antiviral activity induced by culturing lymphocytes with tumor derived or virus transformed cells. Enhancement of human natural killer activity by interfron and antagonistic inhibition of susceptibility of target cells to lysis. J Exp. Med. 1978; 147: 1314–33. Bottazo GF, Todd I, Mirakian R, Belfiore A, Pujol-Borrel R. Organ specific autoimmunity. A 1986 overview. Immunological review. 1986; 94: 153–6. Taylor HG, Nixon NB, Dawest PT. Natural killer cytotoxicity and alpha-interferon in early rheumatoid arthritis. Scand J Rheumatol. 1993; 22: 280–3. Abdelnour A, Bremell Holmdahl R, Tarkowski A. Role of T lymphocytes in experimental Staphylococcus aureus arthritis. Scand J Immunol. 1994; 39: 403–4. Iglesias A, Harold Deulofeut H, Dubey DP, Salazar M, Egea E, Yunis JE, Fraser PA. Functional deficiency of antigen-presenting cells in the synovial fluid of rheumatoid arthritis. Hum. Immunol. 1992; 35: 109–15. Cannon GW, Emkey RD, Denes A, Cohen SA, Saway PA Wolfe F, Jaffer AM, Weaver AL, Cogen L, Gulinello J, Kennedy SM, Schindler JD. Prospective two-year followup of recombinant interferon gamma in rheumatoid arthritis. J. Rheumatol. 1990; 17: 304–31. 31. Coto C, Varela G, Hernández, del Rosario, M, López-Saura, P. Use of recombinant interferon gamma in pediatric patients with advanced juvenile chronic arthritis. Biotherapy 1998; 11: 15–20.